InvestorsHub Logo
Followers 113
Posts 25553
Boards Moderated 4
Alias Born 02/01/2004

Re: None

Wednesday, 02/06/2013 11:18:02 AM

Wednesday, February 06, 2013 11:18:02 AM

Post# of 280
ALN-PCS

Alnylam-MDCO Join for ALN-PCS

by Zacks Equity Research
February 05, 2013

Alnylam Pharmaceuticals Inc. (ALNY - Analyst Report) recently entered into an exclusive global alliance with The Medicines Company (MDCO - Analyst Report) for the development and commercialization of the prior’s ALN-PCS ribo nucleic acid interference (RNAi) therapeutic program.

Currently under development for the treatment of hypercholesterolemia, ALN-PCS RNAi is an important program in Alnylam’s “Alnylam 5x15” strategy.

As per the terms of the collaboration agreement, The Medicines Company will be making an upfront cash payment of $25 million to Alnylam. Alnylam is also eligible to receive up to $180 million on the achievement of development and commercial milestones. The company could also receive scaled double-digit royalties from The Medicines Company on global products sales of the ALN-PCS products commercialized under this agreement.

The collaboration includes ALN-PCS02 and ALN-PCSsc. ALN-PCS02 is an intravenous RNAi therapeutic which completed a phase I trial, whereas ALN-PCSsc, a subcutaneously administered RNAi therapeutic, is currently in pre-clinical development.

Meanwhile, Alnylam is expected to continue with its ALN-PCS program for another one to two years to complete certain pre-clinical and phase I studies. The Medicines Company will be responsible for the development of the candidates from phase II onwards. The Medicines Company will also be responsible for the commercialization of the candidates if the ALN-PCS program is successful.

Earlier this year, Alnylam had provided a brief update on its key “Alnylam 5x15” pipeline, which aims to develop RNAi therapeutic candidates and partner programs for the next couple of years. The company is expecting several study results based on its RNAi therapeutic candidates in the next two years.

We believe that the company is progressing well with its “Alnylam 5x15” pipeline. We expect investor focus to stay on the successful development of the pipeline, though most of them are in early stages of development.

http://www.zacks.com/stock/news/92055/alnylam-mdco-join-for-aln-pcs

April 20, 2012

Tekmira's LNP Technology Enables Alnylam's Positive ALN-PCS Clinical Data

VANCOUVER, British Columbia, April 20, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported that Alnylam Pharmaceuticals, Inc. presented positive clinical results from its Phase 1 clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia, which utilizes Tekmira's lipid nanoparticle (LNP) technology and is manufactured by Tekmira.

"We are pleased this new data from the ALN-PCS human clinical trial continues to demonstrate that Tekmira's leading LNP technology is well tolerated and enables RNAi activity in humans. As the evidence of positive data within the RNAi field continues to grow, we believe that Tekmira's LNP technology is a key driver advancing the field towards the commercialization of RNAi therapeutics for a variety of clinical indications," said Dr. Mark J. Murray, Tekmira's President and CEO.

http://investor.tekmirapharm.com/releasedetail.cfm?ReleaseID=666039